Alvotech’s SEC filings document a foreign private issuer focused on developing and manufacturing biosimilar medicines. Recent Form 6-K reports furnish press releases, earnings materials and business updates covering its biosimilar portfolio, pharmacokinetic studies such as AVT80 compared with Entyvio (vedolizumab), manufacturing compliance matters and FDA inspection outcomes at the Reykjavik facility.
The filing record also describes incorporation by reference into Form F-3, Form F-3ASR and Form S-8 registration statements, together with governance disclosures such as executive team changes. These documents frame Alvotech’s regulatory, operating, capital-markets and reporting activity through current reports and related exhibits.
Alvotech reports that the U.S. FDA has completed a routine cGMP surveillance inspection of its Reykjavik, Iceland manufacturing facility, which ended on May 8, 2026 with the issuance of a Form 483. The company believes the observations can be addressed quickly and do not raise substantial issues with the site or its operations.
Alvotech states it is well positioned to resubmit the relevant Biologics License Applications during the current quarter, after final data are compiled, and continues to expect FDA approval for these BLAs during 2026. The company highlights that the inspection outcome supports the strength of cGMP fundamentals and recent site improvements.
Alvotech reports that the U.S. FDA has completed a routine cGMP surveillance inspection of its Reykjavik, Iceland manufacturing facility, which ended on May 8, 2026 with the issuance of a Form 483. The company believes the observations can be addressed quickly and do not raise substantial issues with the site or its operations.
Alvotech states it is well positioned to resubmit the relevant Biologics License Applications during the current quarter, after final data are compiled, and continues to expect FDA approval for these BLAs during 2026. The company highlights that the inspection outcome supports the strength of cGMP fundamentals and recent site improvements.
Alvotech reported a leadership change, announcing that General Counsel Tanya Zharov has asked to step down after six years with the company. She helped prepare Alvotech for public listings in several jurisdictions and attract international talent to Iceland.
Zharov plans a several-month handover period, continuing to support the company during the transition. She will also take on board responsibilities for Chairman Róbert Wessman’s holding companies, Aztiq and Flóki. Alvotech continues to focus on developing and manufacturing biosimilar medicines, with five biosimilars already approved and marketed in multiple global markets.
Alvotech reported a leadership change, announcing that General Counsel Tanya Zharov has asked to step down after six years with the company. She helped prepare Alvotech for public listings in several jurisdictions and attract international talent to Iceland.
Zharov plans a several-month handover period, continuing to support the company during the transition. She will also take on board responsibilities for Chairman Róbert Wessman’s holding companies, Aztiq and Flóki. Alvotech continues to focus on developing and manufacturing biosimilar medicines, with five biosimilars already approved and marketed in multiple global markets.
Alvotech reported strong 2025 growth with improving profitability and a detailed 2026 outlook. Total revenues reached $593 million, up 21% year-on-year, while adjusted EBITDA rose 27% to $137 million with a 23% margin and gross margin of 61%. The company moved to a net profit of $28 million from a large loss in 2024, supported by higher licensing revenue and favorable non-cash finance items. Cash and cash equivalents were $172 million as of December 31, 2025, and operating cash flow turned positive at $7 million. Several biosimilars, including AVT03, AVT05 and AVT06, were approved in the UK, European Economic Area and Japan, while Selarsdi, referencing Stelara, launched in the United States. For 2026, management guides for total revenues of $650–700 million and adjusted EBITDA of $180–220 million, driven by expansion of commercialized products and efficiency gains, and anticipates late-2026 U.S. approvals for four pending Biologics License Applications.
Alvotech reported strong 2025 growth with improving profitability and a detailed 2026 outlook. Total revenues reached $593 million, up 21% year-on-year, while adjusted EBITDA rose 27% to $137 million with a 23% margin and gross margin of 61%. The company moved to a net profit of $28 million from a large loss in 2024, supported by higher licensing revenue and favorable non-cash finance items. Cash and cash equivalents were $172 million as of December 31, 2025, and operating cash flow turned positive at $7 million. Several biosimilars, including AVT03, AVT05 and AVT06, were approved in the UK, European Economic Area and Japan, while Selarsdi, referencing Stelara, launched in the United States. For 2026, management guides for total revenues of $650–700 million and adjusted EBITDA of $180–220 million, driven by expansion of commercialized products and efficiency gains, and anticipates late-2026 U.S. approvals for four pending Biologics License Applications.
Alvotech’s major shareholders have updated their ownership report. A group of Aztiq- and ATP-affiliated entities now reports beneficial ownership of 103,849,420 ordinary shares, representing 33.3% of Alvotech’s ordinary share class.
The stake includes 95,213,851 ordinary shares and 8,635,569 earnout shares held by Aztiq Pharma Partners, which carry voting rights and will vest only if the share price reaches at least $20.00 for ten trading days within any twenty-day period before June 15, 2027. ATP entities hold additional shares and warrants. Recent transactions include ATP Holdings purchasing 4,812,257 shares at SEK 44.06 (US$4.74) in connection with a concurrent convertible bond offering, selling 2,110,640 of those shares, and a later private transfer of 2,701,617 shares to Aztiq Pharma Partners at US$4.74 per share.
Alvotech’s major shareholders have updated their ownership report. A group of Aztiq- and ATP-affiliated entities now reports beneficial ownership of 103,849,420 ordinary shares, representing 33.3% of Alvotech’s ordinary share class.
The stake includes 95,213,851 ordinary shares and 8,635,569 earnout shares held by Aztiq Pharma Partners, which carry voting rights and will vest only if the share price reaches at least $20.00 for ten trading days within any twenty-day period before June 15, 2027. ATP entities hold additional shares and warrants. Recent transactions include ATP Holdings purchasing 4,812,257 shares at SEK 44.06 (US$4.74) in connection with a concurrent convertible bond offering, selling 2,110,640 of those shares, and a later private transfer of 2,701,617 shares to Aztiq Pharma Partners at US$4.74 per share.
Alvotech reported positive top-line results from a pivotal pharmacokinetic study of AVT80, its proposed subcutaneous biosimilar to Entyvio (vedolizumab). The randomized, double-blind trial in healthy adults met all primary endpoints for pharmacokinetics, safety, tolerability and immunogenicity after a single 108 mg/0.68 mL injection.
The study is considered pivotal to demonstrate clinical similarity for both AVT80 and AVT16, Alvotech’s subcutaneous and intravenous Entyvio biosimilar candidates, and supports progressing toward regulatory submissions. Entyvio generated about US$6.4 billion in combined worldwide net revenues in 2025, highlighting the commercial potential if these biosimilars are eventually approved.
Alvotech reported positive top-line results from a pivotal pharmacokinetic study of AVT80, its proposed subcutaneous biosimilar to Entyvio (vedolizumab). The randomized, double-blind trial in healthy adults met all primary endpoints for pharmacokinetics, safety, tolerability and immunogenicity after a single 108 mg/0.68 mL injection.
The study is considered pivotal to demonstrate clinical similarity for both AVT80 and AVT16, Alvotech’s subcutaneous and intravenous Entyvio biosimilar candidates, and supports progressing toward regulatory submissions. Entyvio generated about US$6.4 billion in combined worldwide net revenues in 2025, highlighting the commercial potential if these biosimilars are eventually approved.
Alvotech has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, Australia and New Zealand. The collaboration is designed to create commercial pathways for Alvotech’s biosimilar portfolio in these markets ahead of regulatory approvals.
In Canada, the agreement covers one ophthalmology biosimilar candidate supplied as a prefilled syringe for intravitreal injection. In Australia and New Zealand, it covers three biosimilar candidates in immunology and gastroenterology, in multiple formulations. Sandoz will handle regulatory submissions, commercialization and distribution, while Alvotech will manage development, global clinical activities and manufacturing and supply finished product under exclusive supply arrangements.
Alvotech has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, Australia and New Zealand. The collaboration is designed to create commercial pathways for Alvotech’s biosimilar portfolio in these markets ahead of regulatory approvals.
In Canada, the agreement covers one ophthalmology biosimilar candidate supplied as a prefilled syringe for intravitreal injection. In Australia and New Zealand, it covers three biosimilar candidates in immunology and gastroenterology, in multiple formulations. Sandoz will handle regulatory submissions, commercialization and distribution, while Alvotech will manage development, global clinical activities and manufacturing and supply finished product under exclusive supply arrangements.
Alvotech has reached a global licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes worldwide for its aflibercept biosimilar to Eylea® 2mg, already approved in the EEA, United Kingdom and Japan.
The deal grants Alvotech worldwide rights to manufacture and supply its commercial partners and sets staged launch dates: marketing and sales from January 1, 2026 in the United Kingdom and Canada, from May 1, 2026 in the European Economic Area and other non‑U.S. countries, and from November 1, 2026 in Japan for all approved indications, alongside a previously announced Q4 2026 license entry date for the U.S., pending regulatory approval.
Alvotech reported regulatory progress for multiple biosimilars in September 2025. Fuji Pharma received Japanese marketing authorization for three Alvotech-developed products: AVT03 (referencing Xgeva/denosumab), AVT05 (referencing Simponi/golimumab) and AVT06 (referencing Eylea/aflibercept). Separately, the European Medicines Agency's CHMP adopted positive opinions recommending approval in the European Economic Area for AVT03 (referencing Prolia/Xgeva) and AVT05 (referencing Simponi); final European Commission decisions are pending. The company furnished press releases as Exhibits 99.1–99.3, which are provided for incorporation by reference but are not being "filed" for certain Exchange Act liabilities.